Related references
Note: Only part of the references are listed.Orally administered cannabidiol does not produce false-positive tests for Δ9-tetrahydrocannabinol on the Securetec DrugWipe® 5S or Drager DrugTest® 5000
Danielle McCartney et al.
DRUG TESTING AND ANALYSIS (2022)
Use and Perceptions of Cannabidiol Products in Canada and in the United States
Samantha Goodman et al.
CANNABIS AND CANNABINOID RESEARCH (2022)
A validated method for the simultaneous quantification of cannabidiol, Δ9-tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trial
Richard C. Kevin et al.
DRUG TESTING AND ANALYSIS (2021)
Medicinal cannabis and driving: the intersection of health and road safety policy
Daniel Perkins et al.
INTERNATIONAL JOURNAL OF DRUG POLICY (2021)
Abrupt withdrawal of cannabidiol (CBD): A randomized trial
Lesley Taylor et al.
EPILEPSY & BEHAVIOR (2020)
Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis
Nicolas J. Schlienz et al.
DRUG AND ALCOHOL DEPENDENCE (2020)
Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users
Tory R. Spindle et al.
DRUG AND ALCOHOL DEPENDENCE (2020)
The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol
Danielle McCartney et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2020)
Robustness of linear mixed-effects models to violations of distributional assumptions
Holger Schielzeth et al.
METHODS IN ECOLOGY AND EVOLUTION (2020)
Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance A Randomized Clinical Trial
Thomas R. Arkell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Access to cannabidiol without a prescription: A cross-country comparison and analysis
Iain S. McGregor et al.
INTERNATIONAL JOURNAL OF DRUG POLICY (2020)
Prescribing medicinal cannabis
Jonathon C. Arnold et al.
AUSTRALIAN PRESCRIBER (2020)
Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects
Hector L. Lopez et al.
JOURNAL OF DIETARY SUPPLEMENTS (2020)
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Tom P. Freeman et al.
LANCET PSYCHIATRY (2020)
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
Thomas R. Arkell et al.
PSYCHOPHARMACOLOGY (2019)
A systematic review of cannabidiol dosing in clinical populations
S. A. Millar et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy
Angela K. Birnbaum et al.
EPILEPSIA (2019)
A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects
Katharina Knaub et al.
MOLECULES (2019)
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Ila M. Linares et al.
BRAZILIAN JOURNAL OF PSYCHIATRY (2019)
A review of effect sizes and their confidence intervals, Part I: The Cohen's d family (vol 14, pg 242, 2018)
Jean-Christophe Goulet-Pelletier et al.
QUANTITATIVE METHODS FOR PSYCHOLOGY (2019)
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele et al.
LANCET (2018)
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs et al.
PSYCHOPHARMACOLOGY (2018)
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Lesley Taylor et al.
CNS DRUGS (2018)
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Sophie A. Millar et al.
FRONTIERS IN PHARMACOLOGY (2018)
Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis A Crossover Trial
Tory R. Spindle et al.
JAMA NETWORK OPEN (2018)
A review of effect sizes and their confidence intervals, Part I: The Cohen's d family
Jean-Christophe Goulet-Pelletier et al.
QUANTITATIVE METHODS FOR PSYCHOLOGY (2018)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life
Antonio W. Zuardi et al.
Frontiers in Pharmacology (2017)
Defining the noninferiority margin and analysing noninferiority: An overview
Turki A. Althunian et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults
David L. Arndt et al.
CANNABIS AND CANNABINOID RESEARCH (2017)
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial
Timna Naftali et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Effects of acute alcohol consumption on measures of simulated driving: A systematic review and meta-analysis
Christopher Irwin et al.
ACCIDENT ANALYSIS AND PREVENTION (2017)
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
Khalid A. Jadoon et al.
DIABETES CARE (2016)
Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy
Istvan Ujvary et al.
CANNABIS AND CANNABINOID RESEARCH (2016)
Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug research
J. L. Veldstra et al.
PSYCHOPHARMACOLOGY (2015)
Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial
Marcos Hortes N. Chagas et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Exercise increases plasma THC concentrations in regular cannabis users
Alexander Wong et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Lack of international consensus in low-risk drinking guidelines
Nina A. F. F. Furtwaengler et al.
DRUG AND ALCOHOL REVIEW (2013)
Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs
Daniel Lakens
FRONTIERS IN PSYCHOLOGY (2013)
At what sample size do correlations stabilize?
Felix D. Schoenbrodt et al.
JOURNAL OF RESEARCH IN PERSONALITY (2013)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
Effects of Benzodiazepines, Antidepressants and Opioids on Driving A Systematic Review and Meta-Analysis of Epidemiological and Experimental Evidence
Tharaka Dassanayake et al.
DRUG SAFETY (2011)
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
Jose Alexandre S. Crippa et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
Mateus M. Bergamaschi et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP)
Joris C. Verster et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2011)
Cannabidiol for the treatment of psychosis in Parkinson's disease
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Development of the Adelaide Driving Self-Efficacy Scale
Stacey George et al.
CLINICAL REHABILITATION (2007)
Share Paper
